These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37689630)

  • 21. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
    Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
    Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 25. The natural history of progressive fibrosing interstitial lung diseases.
    Brown KK; Martinez FJ; Walsh SLF; Thannickal VJ; Prasse A; Schlenker-Herceg R; Goeldner RG; Clerisme-Beaty E; Tetzlaff K; Cottin V; Wells AU
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32217654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
    Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
    Maher TM; Brown KK; Cunningham S; DeBoer EM; Deterding R; Fiorino EK; Griese M; Schwerk N; Warburton D; Young LR; Gahlemann M; Voss F; Stock C;
    Pediatr Pulmonol; 2024 Apr; 59(4):1038-1046. PubMed ID: 38289091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.
    Bowman WS; Newton CA; Linderholm AL; Neely ML; Pugashetti JV; Kaul B; Vo V; Echt GA; Leon W; Shah RJ; Huang Y; Garcia CK; Wolters PJ; Oldham JM
    Lancet Respir Med; 2022 Jun; 10(6):593-602. PubMed ID: 35063079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung function trajectory in progressive fibrosing interstitial lung disease.
    Oldham JM; Lee CT; Wu Z; Bowman WS; Pugashetti JV; Dao N; Tonkin J; Seede H; Echt G; Adegunsoye A; Chua F; Maher TM; Garcia CK; Strek ME; Newton CA; Molyneaux PL
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
    Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
    Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
    Respir Res; 2024 Mar; 25(1):113. PubMed ID: 38448953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
    Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
    Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease.
    Niitsu T; Fukushima K; Komukai S; Takata S; Abe Y; Nii T; Kuge T; Iwakoshi S; Shiroyama T; Miyake K; Tujino K; Tanizaki S; Iwahori K; Hirata H; Miki K; Yanagawa M; Takeuchi N; Takeda Y; Kida H; Kumanogoh A
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36690385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
    Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.